Posted by Michael Wonder on 21 May 2022
Karyopharm and Menarini Group receive positive CHMP opinion for Nexpovio (selinexor) for the treatment of patients with refractory multiple myeloma
20 May 2022 - European Commission decision anticipated within approximately 60 days.
Karyopharm Therapeutics and the Menarini Group today announced that EMA's CHMP has adopted a positive opinion recommending approval of Nexpovio (selinexor), a first-in-class, oral exportin 1 inhibitor, in combination with once weekly bortezomib and low dose dexamethasone for the treatment of adults with multiple myeloma who have received one to three prior lines of therapy.
